रैंकिंग पर वापस जाएं

Henry Schein, Inc. (HSIC)

Fair Value
HealthcareMedical DistributionUnited States

Fundamental

58

मूल्य

$83.97

मार्केट कैप

$9.57B

भाग 1 · कंपनी का मूल्य कितना है

अवलोकन

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users

P/E: 22.9Score: 81Market cap: $99.84B

Cited by Henry Schein as one of two national competitors in medical distribution, McKesson supplies the same office-based physicians and alternate-care sites with pharmaceuticals and medical-surgical products.

P/E: 32.0Score: 83Market cap: $51.78B

Its Medical segment distributes surgical and examination supplies to physician offices, ambulatory surgery centers and home-care providers, the same alternate-care customers Henry Schein Medical serves.

Patterson Companies, Inc. (Patterson Dental)Not tracked

Named in Henry Schein's 10-K as its main U.S. rival, Patterson Dental sells the same consumables, equipment and practice-management software to the same dental offices, and has been privately held since Patient Square Capital took it off Nasdaq in April 2025.

Benco Dental Supply CompanyNot tracked

The third full-service dental distributor in the United States, family-owned and unlisted, competing with Henry Schein practice by practice for the same dental supply and equipment budgets.

Medline Industries, LPNot tracked

The other national medical competitor named in the 10-K, privately held, selling medical-surgical supplies to the same physician practices, surgery centers and long-term care facilities.

बैलेंस शीट और तरलता

राजस्व

$13.60B

पिछले 12 महीने (27/6/2026 तक)

शुद्ध आय

$403M

पिछले 12 महीने (27/6/2026 तक)

Free Cash Flow

$573M

कुल इक्विटी

$3.25B

कुल देनदारियाँ

$6.42B

Current Ratio

1.32

Interest Coverage

4.28

Debt/EBITDA

3.96

Earnings Per Share

राजस्व और शुद्ध आय

Free Cash Flow

आय विवरण

ऐतिहासिक विवरण

समय के साथ मार्जिन

समय के साथ ऋण

ऋण कितना भारी है

वृद्धि तालिका

वृद्धि — राजस्व

Fair Value अनुमान

सामान्य मामलाउचित मूल्यांकित

Fair Value

$77.47

वर्तमान मूल्य

$83.97

Margin of Safety

-8.4%

Fair Value सीमा

$53.98 - $100.95

इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।

अनुमान विधियाँ

विश्लेषकों का लक्ष्य मूल्य:$97.27
डिस्काउंटेड कैश फ्लो (DCF):$97.21
आय गुणक (P/E):$51.61
Graham वृद्धि फॉर्मूला:$43.59
अर्निंग पावर वैल्यू (EPV):$50.50
उचित P/B:$40.68
लाभांश डिस्काउंट (Gordon):इसकी गणना के लिए पर्याप्त डेटा नहीं
P/FFO, परिचालन से प्राप्त निधि:$101.79
मध्य-चक्र आय:$164.55
राजस्व गुणक:$468.49
विश्लेषक सहमति:खरीदें (15B / 9H / 1S)
अंतिम Earnings सरप्राइज़:+0.67%

मूल्यांकन मेट्रिक्स

P/E Ratio

24.48

ROE

12.3%

P/B Ratio

2.96

P/FCF

16.45

Gross Margin

31.3%

ROIC

6.8%

लाभप्रदता Radar

मूल्य सृजन (प्रतिस्पर्धी बढ़त)

ROIC

6.8%

WACC

7.5%

ROIC − WACC

-0.7 pp

ROIC लगभग पूंजी की लागत के बराबर है — कंपनी मुश्किल से अपनी पूंजी लागत की भरपाई कर पा रही है।

Fundamental विश्लेषण मानदंड

पास (18)

  • EPS shows upward trend
  • ROIC 6.8%
  • Gross Margin 31.3%
  • P/FCF 16.45
  • P/B Ratio 2.96
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 12.4%
  • Revenue Growth 5Y 5.4%
  • Analyst Consensus 60% Buy
  • Earnings Surprise avg 3.5%
  • Earnings Quality (OCF/NI) 1.74
  • Share Dilution -4.8%

फेल (9)

  • EPS CAGR 1.29%
  • Price CAGR 3.64%
  • Operating Margin 5.0%
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • PEG Ratio 7.91
  • Net Margin Trend 3.0% vs 3.0%
  • Piotroski F-Score 4/9

अनुपलब्ध (1)

  • Dividend Payout NaN%

Piotroski F-Score

4/9

मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक

score
criteria

Earnings गुणवत्ता

1.74

उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित

शेयर Dilution

-4.8%

शेयर वापस खरीद रही है। शेयरधारक अनुकूल

संस्थागत होल्डिंग

प्रशासन

कार्यकारी टीम

नामपदआयु
Mr. Ronald N. SouthSenior VP & CFO63
Mr. Michael Saul EttingerExecutive VP & COO64
Mr. Mark E. MlotekExecutive VP & Chief Strategic Officer69
Mr. Andrea AlbertiniChief Executive Officer of Global Distribution & Technology55
Mr. Frederick M. LoweryCEO & Director54
Ms. Olga TimoshkinaVP of Corporate Finance & Chief Accounting Officer-
Mr. Christopher PendergastSenior VP & CTO62
Mr. Graham StanleyVP of Investor Relations & Strategic Finance Project Officer-
Ms. Kelly Murphy J.D.Senior VP & General Counsel44
Ms. Christine SheehySenior VP & Chief Human Resources Officer57

Audit जोखिम

4

बोर्ड जोखिम

8

मुआवजा जोखिम

6

शेयरधारक अधिकार जोखिम

4

भाग 2 · कीमत और खरीदने का समय

यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।

दस्तावेज़

  • वार्षिक रिपोर्ट (10-K)

    कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।

    दाखिल तिथि: 2026-02-24

    दस्तावेज़ देखें
  • तिमाही रिपोर्ट (10-Q)

    पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।

    दाखिल तिथि: 2026-08-04

    दस्तावेज़ देखें
  • विशेष रिपोर्ट (8-K)

    किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।

    दाखिल तिथि: 2026-09-22

    दस्तावेज़ देखें

via SEC EDGAR

आय का इतिहास

via SEC EDGAR

Latest News

Recent headlines for HSIC, sourced from Markets Gazette.

  • 6/11/2026POSITIVE
    This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

    Henry Schein Inc. (HSIC) has received a bullish upgrade from Wall Street analysts, signaling a potentially positive outlook for the company's stock. While specific details of the upgrade and the analysts' reasoning are not provided in this snippet, such a shift in sentiment typically suggests that analysts foresee improved financial performance, strategic advantages, or favorable market conditions for HSIC. Investors often view analyst upgrades as a catalyst for stock price appreciation, potentially leading to increased buying interest and upward price momentum.

  • 2/24/2026NEUTRAL
    Henry Schein (HSIC) Q4 2025 Earnings Transcript

    Investors in Henry Schein Inc. (HSIC) are poised to analyze the Q4 2025 earnings transcript, released on February 24, 2026. This event is pivotal for understanding the financial performance of the company, a global leader in distributing healthcare products and services to medical and dental practices. The report's analysis will provide crucial details on revenues, earnings per share (EPS), operating margins, and future outlook, which are fundamental elements for assessing the company's health and potential growth trajectories. While specific data is not yet available for direct evaluation, the transcript's release marks a key moment for the market, allowing deeper insight into management's statements and responses to analyst questions, thereby shaping expectations for the upcoming fiscal period and its impact on share value.

via Markets Gazette

Disclaimer

यह प्लेटफ़ॉर्म केवल शैक्षिक उद्देश्यों के लिए है। यह कोई वित्तीय, निवेश, या ट्रेडिंग सलाह नहीं देता। सभी स्कोर, मूल्यांकन, और संकेत सार्वजनिक रूप से उपलब्ध डेटा के स्वचालित विश्लेषण पर आधारित हैं जो अधूरे या गलत हो सकते हैं। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और एक योग्य वित्तीय सलाहकार से परामर्श लें।

निर्मित द्वारा CODEPRESS s.r.l.